LB-100
MCC-19635
Phase 2 small_molecule active
Quick answer
LB-100 for Myelodysplastic Syndromes is a Phase 2 program (small_molecule) at LIXTE BIOTECHNOLOGY HOLDINGS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- LIXTE BIOTECHNOLOGY HOLDINGS, INC.
- Indication
- Myelodysplastic Syndromes
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active